Blog Band - Page 25 of 299

20

Shots: Health Canada has granted conditional approval (NOC/c) to Amtagvi for adults with unresectable or metastatic melanoma progressing after prior systemic therapy, incl. PD-1 inhibitor &, if BRAF V600 positive,…

20

Aug 2025

NEWS

HUTCHMED Completes Patient Enrolment in P-III (SANOVO) Trial of Orpathys (savolitinib) and Tagrisso (osimertinib) for EGFRm NSCLC

Shots: HUTCHMED has completed enrolment in its P-III (SANOVO) trial to assess Orpathys + Tagrisso as a 1L treatment of pts with locally advanced or metastatic NSCLC harboring EGFR mutation &…

20

Aug 2025

NEWS

VantAI Collaborates with Halda Therapeutics to Discover RIPTAC Medicines

Shots: VantAI has entered into a strategic research collaboration with Halda Therapeutics to advance the discovery & development of selective proximity-based therapies for cancer & immunology indications As per the…

20

Aug 2025

NEWS

Madrigal Pharmaceuticals’ Rezdiffra (Resmetirom) Receives the EC’s Conditional Approval for MASH with Liver Fibrosis

Shots: The EC has granted conditional approval to Rezdiffra to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with mod. to adv. liver fibrosis in 30 EEA states; launch is planned throughout EU…

20

Aug 2025

THOUGHTSPOT

Trends Shaping the Peptide Therapeutics Market in 2025

The peptide therapeutics market in North America and beyond is evolving fast, and 2025 is set to be a groundbreaking year. Whether you’re a researcher involved in peptide drug clinical…

20

Aug 2025

EVENTS

Clinical Trials Operations DACH 2025 | Sep 18 | Basel, Switzerland

This exclusive breakfast meetup is designed for busy Clinical Trials Operation executives who want to gain high-value insights without committing to a full-day event. For any queries, reach out to…

20

Aug 2025

EVENTS

Drug Discovery and Innovation Programme 2025 | Sep 25-26 |Barcelona, Spain

A B2B event designed to connect Drug Discovery Experts, Biotech Innovation, and emerging technologies. This expert-led, two-day event blends keynotes, case studies, panel discussions, and 1:1 meetings to turn research…

19

Aug 2025

INSIGHTS+

EMA Marketing Authorization of New Drugs in July 2025

Shots: The EMA’s CHMP has granted positive opinions and approvals to 3 Biologics and 10 new chemical entities in July 2025, leading to treatments for patients and advances in the…

19

Aug 2025

VIDEO

LIFE SCIENCES DAILY NEWS AUG 19, 2025 PHARMASHOTS

19

Aug 2025

NEWS

ONWARD Medical Receives FDA IDE Approval for ARC-IM System to Treat Blood pressure Instability in Spinal Cord Injury

Shots: ONWARD Medical has received the US FDA IDE approval to initiate its Empower BP study evaluating ARC-IM System for blood pressure instability in spinal cord injury The IDE trial…

Health Canada Grants Conditional Approval to Iovance’s Amtagvi (Lifileucel) for Advanced Melanoma

HUTCHMED Completes Patient Enrolment in P-III (SANOVO) Trial of Orpathys (savolitinib) and Tagrisso (osimertinib) for EGFRm NSCLC

VantAI Collaborates with Halda Therapeutics to Discover RIPTAC Medicines

Madrigal Pharmaceuticals’ Rezdiffra (Resmetirom) Receives the EC’s Conditional Approval for MASH with Liver Fibrosis

Trends Shaping the Peptide Therapeutics Market in 2025

Clinical Trials Operations DACH 2025 | Sep 18 | Basel, Switzerland

Drug Discovery and Innovation Programme 2025 | Sep 25-26 |Barcelona, Spain

EMA Marketing Authorization of New Drugs in July 2025

LIFE SCIENCES DAILY NEWS AUG 19, 2025 PHARMASHOTS

ONWARD Medical Receives FDA IDE Approval for ARC-IM System to Treat Blood pressure Instability in Spinal Cord Injury

Contact US

OUR INFORMATION

FOLLOW US